J Korean Neurosurg Soc.  2021 Nov;64(6):853-863. 10.3340/jkns.2021.0009.

Improved Biocompatibility of Intra-Arterial Poly-L-Lactic Acid Stent by Tantalum Ion Implantation : 3-Month Results in a Swine Model

• Kim K
• Park S
• Park JH
• Cho WS
• Kim HE
• Lee SM
• Kim JE
• Kang HS
• Jang TS

• KMID: 2521975
• DOI: http://doi.org/10.3340/jkns.2021.0009

Abstract

Objective
: Biodegradable poly-L-lactic acid (PLLA) with a highly biocompatible surface via tantalum (Ta) ion implantation can be an innovative solution for the problems associated with current biodegradable stents. The purpose of this study is to develop a Ta-implanted PLLA stent for clinical use and to investigate its biological performance capabilities.
Methods
: A series of in vitro and in vivo tests were used to assess the biological performance of bare and Ta-implanted PLLA stents. The re-endothelialization ability and thrombogenicity were examined through in vitro endothelial cell and platelet adhesion tests. An in vivo swine model was used to evaluate the effects of Ta ion implantation on subacute restenosis and thrombosis. Angiographic and histologic evaluations were conducted at one, two and three months post-treatment.
Results
: The Ta-implanted PLLA stent was successfully fabricated, exhibiting a smooth surface morphology and modified layer integration. After Ta ion implantation, the surface properties were more favorable for rapid endothelialization and for less platelet attachment compared to the bare PLLA stent. In an in vivo animal test, follow-up angiography showed no evidence of in-stent stenosis in either group. In a microscopic histologic examination, luminal thrombus formation was significantly suppressed in the Ta-implanted PLLA stent group according to the 2-month follow-up assessment (21.2% vs. 63.9%, p=0.005). Cells positive for CD 68, a marker for the monocyte lineage, were less frequently identified around the Ta-implanted PLLA stent in the 1-month follow-up assessments.
Conclusion
: The use of a Ta-implanted PLLA stent appears to promote re-endothelialization and anti-thrombogenicity.

Keyword

Absorbable implants; Lactic acid; Stents; Tantalum; Pig

Figure

• 

  Fig. 1. Schematic illustration of the tantalum (Ta) implantation treatment on a poly-L-lactic acid (PLLA) stent. Ta ions were accelerated toward the surface of the PLLA stent, where high negative voltage was applied, forming a Ta-implanted polymer layer.

• 

  Fig. 2. Poly-L-lactic acid (PLLA) stent manufactured by laser cutting. The PLLA stent is mounted on a coronary balloon with a gold marker, which is identified in the fluoroscopic image.

• 

  Fig. 3. Surface morphology of the stent. Optical (A) and scanning electron microscope (B) images of bare and tantalum (Ta)-implanted poly-L-lactic acid (PLLA) stents. The PLLA stent shows a smooth surface. There is no difference in the surface morphology of the PLLA stent before and after Ta implantation treatment.

• 

  Fig. 4. Roughness of the stent. A : Surface topography 3D maps of bare and tantalum (Ta)-implanted poly-L-lactic acid (PLLA) stents. B : There is no significant difference in the calculated average roughness on each surface.

• 

  Fig. 5. Water contact angle test. The tantalum (Ta) treatment increased the wettability of the stent. *p<0.05.

• 

  Fig. 6. Radial force of the poly-L-lactic acid (PLLA) stent (no significant difference).

• 

  Fig. 7. Tantalum layer of the poly-L-lactic acid (PLLA) stent. Representative cross-sectional transmission electron microscope (TEM) image and the TEM/energy-dispersive spectroscopy line profile with c, O, and tantalum (Ta) along the white line from points a to b on the (A) luminal surface and (B) the abluminal surface of the Ta-implanted PLLA stent.

• 

  Fig. 8. Endothelialization test. A : confocal laser scanning microscopy images of adhered endothelial cells. Surface coverage of endothelial cells (B) and cell viability (c) on bare and tantalum (Ta)-implanted poly-L-lactic acid (PLLA) surfaces after 1, 4, and 7 days of culturing, respectively. *p<0.05. †p<0.01.

• 

  Fig. 9. Platelet adhesion test. A : Scanning electron microscope images of the adhered platelet morphology on bare and tantalum-implanted poly-L-lactic acid (PLLA) stents. B : Absorbance difference between 492 nm and 690 nm of a platelet-lysed solution and (c) the number of adhered platelets on each PLLA stent from the lactate dehydrogenase assay. *p<0.05.

• 

  Fig. 10. Angiographic and histologic results (×40 magnification) 3 months after stent deployment. A : All parent arteries are patent in the angiographic images without in-stent stenosis (right : tantalum-implanted poly-L-lactic acid [PLLA] stent, left : bare PLLA stent). The black arrows indicate the gold marker of the stent. B : After tissue preparation and hematoxylin and eosin staining with identical specimens, many specimens demonstrate what appears to be an arterial lumen collapse despite the lack of evidence of stenosis in the angiographic images. The discrepancy between the angiographic and histological results may be due to issues that arose during the tissue preparation step with paraffin embedding for the immunohistochemical analysis and stent characteristics such as the small diameter and weak radial force (right : tantalum-implanted PLLA stent, left : bare PLLA stent).

• 

  Fig. 11. In vivo thrombogenicity. The tantalum (Ta)-implanted poly-L-lactic acid stent group shows less thrombus formation according to the 2-month follow-up exam (21.2% vs. 63.9%, p=0.005).

• 

  Fig. 12. In vivo inflammation. Less of an inflammatory reaction is identified in the tantalum (Ta)-implanted poly-L-lactic acid (PLLA) stent group at 1-month follow-up. The numbers of cD68+ cells/400 HPF are 5.2±7.3 in the Ta-implanted PLLA stent group (A) and 9.0±16.2 in the bare PLLA stent group (B) (×200 magnification). However, these outcomes lack statistical significance (p=0.601). c : The inflammatory response decreases with time.

Reference

References

1. Barbarash LS, Bolbasov EN, Antonova LV, Matveeva VG, Velikanova EA, Shesterikov EV, et al. Surface modification of poly-ε-caprolactone electrospun fibrous scaffolds using plasma discharge with sputter deposition of a titanium target. Materials Letters. 171:87–90. 2016.

2. Bledzki AK, Jaszkiewicz A, Scherzer D. Mechanical properties of PLA composites with man-made cellulose and abaca fibres. Compos Part A Appl Sci Manuf. 40:404–412. 2009.

3. Chen JY, Leng YX, Tian XB, Wang LP, Huang N, Chu PK, et al. Antithrombogenic investigation of surface energy and optical bandgap and hemocompatibility mechanism of Ti(Ta+5)O2 thin films. Biomaterials. 23:2545–2552. 2002.

4. Collet C, Asano T, Miyazaki Y, Tenekecioglu E, Katagiri Y, Sotomi Y, et al. Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 38:2559–2566. 2017.

5. Hanawa T. Metal ion release from metal implants. Mat Sci Eng C-Bio S. 24:745–752. 2004.

6. Hou LD, Li Z, Pan Y, Sabir M, Zheng YF, Li L. A review on biodegradable materials for cardiovascular stent application. Front Mater Sci. 10:238–259. 2016.

7. Hu T, Yang C, Lin S, Yu Q, Wang G. Biodegradable stents for coronary artery disease treatment: recent advances and future perspectives. Mater Sci Eng C Mater Biol Appl. 91:163–178. 2018.

8. Hwang G, Kim JG, Song KS, Lee YJ, Villavicencio JB, Suroto NS, et al. Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy. Radiology. 273:194–201. 2014.

9. Ikarashi Y, Toyoda K, Ohsawa N, Uchima T, Tsuchiya T, Kaniwa M, et al. Comparative studies by cell culture and in vivo implantation test on the toxicity of natural rubber latex materials. J Biomed Mater Res. 26:339–356. 1992.

10. Jin W, Wang G, Lin Z, Feng H, Li W, Peng X, et al. Corrosion resistance and cytocompatibility of tantalum-surface-functionalized biomedical ZK60 Mg alloy. Corros Sci. 114:45–56. 2017.

11. Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. J Am Coll Cardiol. 70:2852–2862. 2017.

12. Krischek Ö, Miloslavski E, Fischer S, Shrivastava S, Henkes H. A comparison of functional and physical properties of self-expanding intracranial stents [Neuroform3, Wingspan, Solitaire, Leo(+), Enterprise]. Minim Invasive Surg. 54:21–28. 2011.

13. Nie FL, Zheng YF, Wang Y, Wang JT. Microstructures, mechanical behavior, cellular response, and hemocompatibility of bulk ultrafine-grained pure tantalum. J Biomed Mater Res B Appl Biomater. 102:221–230. 2014.

14. Park C, Seong YJ, Kang IG, Song EH, Lee H, Kim J, et al. Enhanced osseointegration ability of poly(lactic acid) via tantalum sputtering-based plasma immersion ion implantation. ACS Appl Mater Interfaces. 11:10492–10504. 2019.

15. Pizzoferrato A, Ciapetti G, Savarino L, Stea S, Tarabusi C. Results of histological grading on 100 cases of hip prosthesis failure. Biomaterials. 9:314–318. 1988.

16. Räber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Koppara T, et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 66:1901–1914. 2015.

17. Rasal RM, Janorkar AV, Hirt DE. Poly(lactic acid) modifications. Prog Polym Sci. 35:338–356. 2010.

18. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 19:267–274. 1992.

19. Sharkawi T, Cornhill F, Lafont A, Sabaria P, Vert M. Intravascular bioresorbable polymeric stents: a potential alternative to current drug eluting metal stents. J Pharm Sci. 96:2829–2837. 2007.

20. Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 392:1530–1540. 2018.

21. Suyatma NE, Copinet A, Tighzert L, Coma V. Mechanical and barrier properties of biodegradable films made from chitosan and poly (lactic acid) blends. J Polym Environ. 12:1–6. 2004.

22. Tverdokhlebov SI, Bolbasov EN, Shesterikov EV, Antonova LV, Golovkin AS, Matveeva VG, et al. Modification of polylactic acid surface using RF plasma discharge with sputter deposition of a hydroxyapatite target for increased biocompatibility. Appl Surf Sci. 329:32–39. 2015.

23. Wang J, Jin X, Huang Y, Ran X, Luo D, Yang D, et al. Endovascular stent-induced alterations in host artery mechanical environments and their roles in stent restenosis and late thrombosis. Regen Biomater. 5:177–187. 2018.

24. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 64:2541–2551. 2014.